United Pompe Foundation
  • Home
  • About
  • Clinical Trial Process
  • Donations
  • Events
  • Resources
    • EP Magazine Article
    • Videos
    • Related Articles
    • Pompe Links
  • Contact Us
Select Page

Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease

by United Pompe | Jan 18, 2016 | News

Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease

Sanofi-aventis to Acquire Genzyme

by United Pompe | Jan 18, 2016 | News

Sanofi-aventis to Acquire Genzyme

POMPE in COMMON

by United Pompe | Jan 18, 2016 | News

POMPE in COMMON

United States Pompe Program Update, August 9, 2010

by United Pompe | Jan 18, 2016 | News

United States Pompe Program Update, August 9, 2010

United States Pompe Program Update, May 25, 2010

by United Pompe | Jan 18, 2016 | News

United States Pompe Program Update, May 25, 2010
« Older Entries
Next Entries »

Recent Posts

  • A Primer for Family Medicine and Primary Care: Focusing on Pompe Disease
  • POMPE Survey
  • Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
  • CLINICAL TRIALS/STUDIES
  • Higher Lumizyme Dose May Help Prevent Pompe Progression in Infants, Case Report Suggests

Archives

  • September 2019
  • March 2019
  • September 2018
  • August 2018
  • July 2018
  • March 2017
  • December 2016
  • November 2016
  • July 2016
  • January 2016
  • October 2014

About

The United Pompe Foundation was formed to assist patients and/or their families with medical costs and other expenses that these patients and families face and may not be able to cover, or fully cover, through their insurance.

Contact

United Pompe Foundation
5100 N. Sixth Street #119
Fresno, CA 93710

Email: [email protected]
Phone: (559) 227-1898
Fax: (559) 227-1898

Copyright © 2018 United Pompe Foundation | All Rights Reserved | WUR